Article Information
History
- November 5, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Sarita Rani Jaiswal1,2,5,
- Ashraf Saifullah2,
- Jaganath Arunachalam1,
- Rohit Lakhchaura2,
- Dhanir Tailor6,
- Anupama Mehta2,
- Gitali Bhagawati3,
- Hemamalini Aiyer3,
- Subhrajit Biswas5,
- Bakulesh Khamar4,
- Sanjay V. Malhotra6,* and
- Suparno Chakrabarti1,2,*
- 1Cellular Therapy and Immunology, Manashi Chakrabarti Foundation, New Delhi, India
- 2Department of Blood and Marrow Transplantation, India
- 3Department of Pathology and Microbiology, Dharamshila Narayana Super-speciality Hospital, India
- 4Research & Development, Cadila Pharmaceuticals Ltd, Ahmedabad, India
- 5Amity Institute of Molecular Medicine and Stem Cell Research, Amity University, Noida, Uttar Pradesh, India
- 6Department of Cell, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer Institute, Oregon Health & Science University, Portland, OR, USA
- ↵*CORRESPONDENCE:
Suparno Chakrabarti, Cellular Therapy and Immunology, Manashi Chakrabarti Foundation, Vasundhara Enclave, New Delhi-110096, India, Email: foundationforcure{at}gmail.com & Sanjay V. Malhotra, Development & Cancer Biology and Center for Experimental Therapeutics, Knight Cancer, Institute, Oregon Health & Science University, Portland, OR, USA, Email: malhotsa{at}ohsu.edu
Posted November 05, 2022.
Augmenting vaccine efficacy against delta variant with ‘Mycobacterium-w’ mediated modulation of NK-ADCC and TLR-MYD88 pathways
